Neurology® Podcast

1) The takeaway Frenzel goggles: a Fresnel-based device and 2) Topic of the month: Management of sports concussion. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Reza Seyedsadjadi interviews Dr. Michael Strupp about his paper on the takeaway Frenzel goggles: a Fresnel-based device. Dr. James Addington is reading our e-Pearl of the week about steroid-responsive encephalopathy. In the next part of the podcast Dr. Stephen Donahue interviews Dr. Michael Jaffee about the impact of concussion and traumatic brain injury in society. The participants had nothing to disclose except Drs. Strupp, Addington and Jaffee.Dr. Strupp serves as Joint-Chief Editor of the Journal of Neurology, Editor-in-Chief of Frontiers in Neuro-otology Section Editor of F1000; serves on the scientific advisory board for Abbott and Pierre-Fabre; receives royalties from the publication of the book Vertigo and dizziness - common complaints; received speaker honoraria from Abbott, GlaxoSmithKline, Merck Serono, Henning Arzneimittel GmbH & Co. KG, Pierre Fabre Laboratories, UCB and Eisai Inc. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jaffee serves on the scientific advisory boards for WETA (Public Television) Brainline, U. S. Army Peer Review Alzheimer Research Program and the NIH translational research outcome consortium review.

1) Editorial on his career-ending traumatic brain injury and his concerns about the consequence of such injuries for his future and for others affected and 2) Topic of the month: Management of sports concussion. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Mr. Ben Utecht about his editorial on his career-ending traumatic brain injury and his concerns about the consequence of such injuries for his future and for others affected. Dr. James Addington is reading our e-Pearl of the week about POTS syndrome. In the next part of the podcast Dr. Stephen Donahue interviews Dr. Michael Jaffee about the management of patients with chronic issues related to post concussive symptoms. The participants had nothing to disclose except Drs. Burns, Addington, Jaffee and Mr. Utecht.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Mr. Utecht serves as a spokesperson for the AAN/ABF.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jaffee serves on the scientific advisory boards for WETA (Public Television) Brainline, U. S. Army Peer Review Alzheimer Research Program and the NIH translational research outcome consortium review.

1) Course of psychiatric symptoms and global cognition in early Parkinson disease and 2) Topic of the month: Management of sports concussion. This podcast for the Neurology Journal begins and closes with Dr. Ted Burns, Section Editor Podcasts, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matt Barrett interviews Dr. Dan Weintraub about his paper on the course of psychiatric symptoms and global cognition in early Parkinson disease. Dr. James Addington is reading our e-Pearl of the week about KCNQ2 in early onset epileptic encephalopathy. In the next part of the podcast Dr. Stephen Donahue interviews Dr. Michael Jaffee about the management of concussion after the diagnosis has been made and the recommendation for graduated return to play or normal activities. The participants had nothing to disclose except Drs. Barrett, Weintraub, Addington and Jaffee.Dr. Barrett receives research support from the Virginia Center of Alzheimer's and Related Diseases Research Award Fund.Dr. Weintraub serves as an editorial board member of Movement Disorders Journal and Journal of Parkinson's disease; serves on the scientific advisory boards of Pfizer Inc, Teva Pharmaceuticals Industries Ltd., Avanir Pharmaceuticals, Merck Serono, Lundbeck Inc., UCB, Bristol-Myers Squibb, Novartis, Clintrex, Theravance, Medication Non-profit-CHDI, ADCS; receives license fee payments from the University of Pennsylvania for licensing of questionnaire for impulsive-compulsive disorders in Parkinson disease and QUIP and QUIP-RS; gave expert testimony for defense in two lawsuits related to impulse control disorders in Parkinson disease; receives research support from Michael J. Fox Foundation, Department of Veterans Affairs, Novartis and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jaffee serves on the scientific advisory boards for WETA (Public Television) Brainline, U. S. Army Peer Review Alzheimer Research Program and the NIH translational research outcome consortium review.

1) Mirror therapy in unilateral neglect after stroke and 2) Topic of the month: Management of sports concussion. This podcast for the Neurology Journal begins and closes with Dr. Ted Burns, Section Editor Podcasts, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Jeyaraj Pandian about his paper on mirror therapy in unilateral neglect after stroke. Dr. James Addington is reading our e-Pearl of the week about basilar-type migraine. In the next part of the podcast Dr. Stephen Donahue interviews Dr. Michael Jaffee about the acute diagnosis and management of concussion. The participants had nothing to disclose except Drs. Southerland, Pandian, Addington and Jaffee.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Pandian serves as Editor-in-Chief of CHRISMED J Health and Research; serves on the scientific advisory board of International J Stroke and serves as an Associate Editor for the Neurology India Journal.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jaffee serves on the scientific advisory boards for WETA (Public Television) Brainline, U. S. Army Peer Review Alzheimer Research Program and the NIH translational research outcome consortium review.

1) Current practices in feeding tube placement for US acute ischemic stroke inpatients and 2) Topic of the month: Management of sports concussion. This podcast for the Neurology Journal begins and closes with Dr. Ted Burns, Section Editor Podcasts, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Drs. Ben George and Adam Kelly about their paper on current practices in feeding tube placement for US acute ischemic stroke inpatients. Dr. James Addington is reading our e-Pearl of the week about childhood stroke: think metabolic. In the next part of the podcast Dr. Stephen Donahue interviews Dr. Michael Jaffee about the definition of concussion and how the grading has evolved over recent years. The participants had nothing to disclose except Drs. Barrett, George, Kelly, Addington and Jaffee.Dr. Barrett serves as an editorial board member of Neurology; serves as an Associate Editor of Neurohospitalist and receives research support from the NIH.Dr. George receives research support from the American Heart Association/American Stroke Association and the Parkinson's disease Foundation.Dr. Kelly serves as an editorial board member of Continuum; serves as Guest Editor for Cerebrovascular Disease issue, April 2014 and received research support from the Donald W. Reynolds Foundation.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jaffee serves on the scientific advisory boards for WETA (Public Television) Brainline, U. S. Army Peer Review Alzheimer Research Program and the NIH translational research outcome consortium review.

Area of functional symptoms & conversion disorders. Lesson of the Week interviews from November 2013.

1) Growth hormone treatment for childhood short stature and risk of stroke in early adulthood and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Cyrus Boelman interviews Dr. Emmanuel Touze about his paper on growth hormone treatment for childhood short stature and risk of stroke in early childhood. Dr. Adam Numis is reading our e-Pearl of the week about LG-1 antibodies in limbic encephalitis. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Don Levy about approaches of Integrative Medicine practitioners to patient care. The participants had nothing to disclose except Dr. Numis.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.

1) A clinical pathologic study of depressive symptoms and cognitive decline in old age and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Robert S. Wilson about his paper on depressive symptoms and cognitive decline in old age. Dr. Adam Numis is reading our e-Pearl of the week about ictal syncope. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Tieraona Low Dog about complementary alternative medicine therapies using supplements for treatment of headaches. The participants had nothing to disclose except Drs. Burns, Wilson and Numis. Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials. Dr. Wilson serves as a Consulting Editor of Aging, Neuropsychology and Cognition, Psychology and Aging, and Neuropsychology; is a consultant for Pain Therapeutics, Inc.; and receives research support from the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Untreated brain arteriovenous malformations: Patient level meta-analysis of hemorrhage predictors and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeremy Lanford interviews Dr. Helen Kim about her paper on untreated brain arteriovenous malformations. Dr. Adam Numis is reading our e-Pearl of the week about spinal epidural abscesses. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Remy Coeytaux about complementary alternative medicine to chronic pain and integrative medicine approaches. The participants had nothing to disclose except Drs. Coeytaux and Numis.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Coeytaux is a consultant for Samueli Institute and receives research support from the NIH.

1) Palliative care and neurology: Time for a paradigm shift and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Bragg interviews Dr. Benzi Kluger about his paper on palliative care and neurology: Time for a paradigm shift. Dr. Adam Numis is reading our e-Pearl of the week about intravascular B-cell lymphoma. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Pushpa Narayanaswami about complementary alternative medicine therapies for patients with multiple sclerosis. The participants had nothing to disclose except Drs. Kluger, Numis, and Narayanaswami.Dr. Kluger serves as an editorial board member of Frontiers in Movement Disorders; received speaker honoraria from Teva Pharmaceutical Industrials Ltd., Parkinson's Association of the Rockies and National Parkinson's Foundation; receives research support from the US Army Research Laboratory and US Army Research Office, Veterans Affairs Medical Center CRICC Program, Michael J. Fox Foundation, University of Colorado Hospital Clinical Effectiveness and Patient Safety Program and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Narayanaswami serves as an editorial board member of Neurology® Level of Evidence Review Team; is a consultant for Blue Cross Blue Shield of Massachusetts, Pharmacy and Therapeutics Committee, Advanced Medical and Boston Clinical Research Institute; performs EMG in her clinical practice (35% effort); receives research support from Merz Pharmaceuticals, Inc., Solstice Pharma and AHRQ; received research support from the NIH.

Viral meningoencephalitides, lyme disease, & bacterial meningoencephalitides. Lesson of the week interviews from June 2014.

1) Evaluation and construction of diagnostic criteria for inclusion body myositis and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Steven A. Greenberg about his paper on evaluation and construction of diagnostic criteria for inclusion body myositis. Dr. James Addington is reading our e-Pearl of the week about Rapid-Onset Dystonia Parkinsonism. In the next part of the podcast Dr. Alberto Espay continues his interview with Dr. Jon Stone including questions about his Contemporary Clinical Issues Lecture about functional (psychogenic) disorders in neurology from the audience at Interview Central and his responses. The participants had nothing to disclose except Drs. Burns, Greenberg, Addington, Espay and Stone.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Greenberg is a consultant for MedImmune, aTyr Pharma; receives publishing royalties from the publication of the book EMG Pearls; receives license fee payments from Composition and Methods for Diagnosing and Assessing Inflammatory Myopathies, MedImmune; receives revenue for patents for composition and methods for diagnosing and assessing inflammatory myopathies, detecting inclusion body myositis; receives research support from MedImmune, Novartis and the NIH; serves on the scientific advisory board for MedImmune; received funding for travel from Biogen Idec and Genzyme Corporation.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Stone received speaker honoraria from the Movement Disorders Society, British Medical Association, American Academy of Neurology Royal College of Psychiatrists, UCB Pharma, Novartis, Tribunals Judiciary (UK); receives research support from the National Research Strategy Career Fellow with NHS Scotland Research; receives publishing royalties from UptoDate 2014; runs a free self-help website for patients with functional disorders www.neurosymptoms.org; carries out regular expert witness work in relation to personal injury and medical negligence.

1) Traumatic brain injury and risk of dementia in older veterans and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Farrah Mateen interviews Dr. Deborah Barnes about her paper on traumatic brain injury and risk of dementia in older veterans. Dr. James Addington is reading our e-Pearl of the week about chronic traumatic encephalopathy. In the next part of the podcast Dr. Alberto Espay interviews Dr. Jon Stone about his Contemporary Clinical Issues Lecture at the AAN Meeting about functional (psychogenic) disorders in neurology. The participants had nothing to disclose except Drs. Mateen, Barnes, Addington, Espay and Stone.Dr. Mateen received funding support from the Canadian Institute of Health Research.Dr. Barnes receives research support from UCB, Department of Defense, Department of Veterans Affairs, NARSAD (Brain & Behavior Research Foundation), S.D. Bechtel Jr. Foundation, philanthrophic support via Osher Center for Integrative Medicine, University of California, San Francisco, patient centered outcomes research institute and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Stone received speaker honoraria from the Movement Disorders Society, British Medical Association, American Academy of Neurology Royal College of Psychiatrists, UCB Pharma, Novartis, Tribunals Judiciary (UK); receives research support from the National Research Strategy Career Fellow with NHS Scotland Research; receives publishing royalties from UptoDate 2014; runs a free self-help website for patients with functional disorders www.neurosymptoms.org; carries out regular expert witness work in relation to personal injury and medical negligence.

1) Defining the clinical course of multiple sclerosis: The 2013 revisions and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Fred Lublin about his paper on defining the clinical course of multiple sclerosis: The 2013 revisions. Dr. James Addington is reading our e-Pearl of the week about familial fatal insomnia. In the next part of the podcast Dr. Alberto Espay interviews Dr. David Eidelberg about his Hot Topics Lecture at the AAN Meeting about functional connectivity and functional imaging in movement disorders. The participants had nothing to disclose except Drs. Keegan, Lublin, Addington, Espay and Eidelberg.Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Lublin serves as co-Chief Editor of Multiple Sclerosis and Related Disorders; serves on the scientific advisory boards and as a consultant for Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Teva Pharmaceutical Industries Ltd., Actelion Pharmaceuticals Ltd, Sanofi-aventis, Acorda Therapeutics Inc, Questcor Pharmaceuticals, Roche, Genentech, Inc., Celgene, Johnson & Johnson, Revalesio Corporation, Coronado Bioscience, Genzyme Corporation, MedImmune, Bristol-Myers Squibb, XenoPort, Inc., Receptos Inc, Forward Pharma, to- BBB technologies; receives research support from Biogen Idec, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc, Novartis, Genzyme Corporation, Sanofi-aventis, Celgene, National Multiple Sclerosis Society and the NIH; holds financial interests/stock options in Cognition Pharmaceuticals. Inc. and may discuss unapproved agents that are in the MS developmental pipeline with any recommendations on their use.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Eidelberg serves as an Associate Editor of Journal of Neuroscience; serves as an editorial board member of Journal of Nuclear Medicine, Current Opinion in Neurology, Annals of Neurology and NeuroImage; serves on the scientific advisory board for the Michael J. Fox Foundation, ; co-inventor of United States Patent No. 5, 632,276 and No. 5,873,823 without financial gain; receives research support from the Michael J. Fox Foundation and the NIH.

1) Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Russell Dale about his paper on utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Dr. James Addington is reading our e-Pearl of the week about pseudo-internuclear ophthalmoplegia. In the next part of the podcast Dr. Alberto Espay interviews Dr. David Holtzman about his Robert Wartenberg Lecture at the AAN Meeting about Alzheimer's disease in 2014: Mapping a road forward. The participants had nothing to disclose except Drs. Dale, Addington, Espay and Holtzman.Dr. Dale serves on the scientific advisory board for Queensland Children's Medical Institute; serves as an editorial advisory board member of Multiple Sclerosis and Related Disorders Journal; received honoraria for lecturing from Biogen Idec; receives research support from the National Health and Medical Research Council. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Holtzman serves as an Associate Editor of Annuals of Neurology; serves as an editorial board member of Neurobiology of Disease, Experimental Neurology, Molecular Neurodegeneration, Science Translational Medicine and Journal of Experimental Medicine; co-founder of C2N Diagnostic LLC; is a consultant for AstraZeneca, Genentech, Inc., Bristol-Myers Squibb and Forum Pharmaceuticals; receives research support AstraZeneca, Eli Lilly and Company, Biogen Idec, C2N Diagnostic LLC, Cure Alzheimer's Disease, Tau Consortium, Ellison Medical Foundation and the NIH.

Topics in critical care neurology. Lessons of the week from May 2014

1) Long-term safety and effectiveness of natalizumab for re-dosing and treatment of multiple sclerosis and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ruth Ann Marrie interviews Dr. Paul O'Connor about his paper on long-term safety and effectiveness of natalizumab for re-dosing and treatment of multiple sclerosis. Dr. James Addington is reading our e-Pearl of the week about inclusion body myositis. In the next part of the podcast Dr. Alberto Espay interviews Dr. James Bernat about his Presidential Lecture at the AAN Meeting about challenges to ethics and professionalism facing the contemporary neurologist. The participants had nothing to disclose except Drs. Marrie, O'Connor, Addington, Espay and Bernat.Dr. Marrie serves on the editorial board for Neurology® and Multiple Sclerosis Journal; receives research support from Sanofi-aventis, Canadian Institutes of Health Research, Public Health Agency of Canada, Multiple Sclerosis Society of Canada, National Multiple Sclerosis Society, Multiple Sclerosis Scientific Foundation and Consortium of Multiple Sclerosis Centers.Dr. O'Connor served on the editorial advisory board of the MS Journal; serves on the scientific advisory board for Novartis, Sanofi-aventis, Bravo Pharmaceuticals, Genentech, Inc., Roche and Actelion Pharmaceuticals Ltd; is a consultant for Biogen Idec, Teva Pharmaceutical Industries Ltd., Sanofi-aventis and Novartis; received funding for travel to advisory board meeting in Toronto; receives research support from Novartis, Sanofi-aventis, Roche, Biogen Idec and as National Scientific and Clinical Advisor to the MS Society of Canada. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Bernat serves as an unpaid editorial board member of Neurocritical Care, Neurology Today, and Multiple Sclerosis and Related Diseases; a paid editorial board member of The Physician's Index for Ethics and Medicine; and receives royalties from the publication of the books Ethical Issues in Neurology, 3rd ed, Palliative Care in Neurology, and Ethical and Legal Issues in Neurology.

1) Factors associated with recovery from acute optic neuritis in multiple sclerosis and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Tanuja Chitnis about her paper on factors associated with recovery from acute optic neuritis in multiple sclerosis. Dr. Adam Numis is reading our e-Pearl of the week about tanycytic ependymal tumors. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Karen Roos about neurology and infectious diseases: Bacterial meningoencephalitides. The participants had nothing to disclose except Drs. Jen, Tedeschi, Numis and Roos.Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Chitnis is a consultant for Biogen Idec, Teva Pharmaceutical Industries Ltd., Novartis, Sanofi-aventis; receives research support from Merck Serono and Novartis in the form of Independent Investigator Awards, National Multiple Sclerosis Society. the Peabody Foundation and the Guthy-Jackson Charitable Foundation.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Roos receives royalties for five published books.

1) Abnormal thalamic function in patients with vestibular migraine and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Joanna Jen interviews Dr. Gioacchino Tedeschi about his paper on abnormal thalamic function in patients with vestibular migraine. Dr. Adam Numis is reading our e-Pearl of the week about Gerstmann-Straussler-Scheinker syndrome. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Karen Roos about neurology and infectious diseases: Lyme disease. The participants had nothing to disclose except Drs. Jen, Tedeschi, Numis and Roos.Dr. Jen serves as a Section Editor for Experimental Brain Research; serves as an Associate Editor for Frontiers in Neuro-otology; receives research support from the FDA.Dr. Tedeschi receives speaker honoraria from Novartis, Schwarz Pharma AG, UCB, Lundbeck Inc., GlaxoSmithKline and AbbVie.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Roos receives royalties for five published books.

1) Anti-agrin autoantibodies in myasthenia gravis and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Arthur Melms about his paper on anti-agrin autoantibodies in myasthenia gravis. Dr. Adam Numis is reading our e-Pearl of the week about myopathy masquerading as myasthenia. In the next part of the podcast Dr. Chenjie Xia interviews Drs. Maria Nagel and Don Gilden about neurology and infectious diseases: Viral meningoencephalitides. The participants had nothing to disclose except Drs. Burns, Melms, Numis, Nagel and Gilden.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Melms performs clinical procedures as Professor of Neurology and Neurorehabilitation at the University of Erlangen, Germany (20%) and is clinical director of a privately owned neurological rehabilitation hospital (80%); clinical research is supported by the Ernst Freiberger Foundation, Berlin, Germany; received speaker honoraria from GlaxoSmithKline; received research support from German Research Agency, Collaborative Research Center 685, Immunotherapy, and the Gemeinützige Hertie Foundation, Frankfurt/Main, Germany.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Nagel receives research support from the NIH.Dr. Gilden serves as Senior Associate Editor of Journal of NeuroVirology; serves as an editorial board member of In Vivo, Journal of Virology; Scientific American Medicine, Virus Genes, Neurology Journal, receives research support from the NIH.

Parkinson's & parkinsonism disorders. Lesson of the Week interviews from January 2014.

1) Effects of cannabis on cognition in patients with multiple sclerosis and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Menze interviews Dr. Anthony Feinstein about his paper on the effects of cannabis on cognition in patients with multiple sclerosis. Dr. James Addington is reading our e-Pearl of the week about spinal dural arteriovenous fistula. In the next part of the podcast Dr. Mike Brogan interviews Dr. Claude Hemphill about the management of intracranial hypertension. The participants had nothing to disclose except Drs. Feinstein, Addington and Hemphill.Dr. Feinstein serves as an editorial board member of Multiple Sclerosis and African Journal of Psychiatry; receives royalties from the publication of the book The Clinical Neuropsychiatry of Multiple Sclerosis; performs neuropsychiatric evaluation, cognitive testing, brain imaging in neuropsychiatry clinical practice; receives research support from Biogen Idec, Canadian Institute of Health Research, Multiple Sclerosis Society of Canada and University of Toronto; received honoraria for lectures from Merck Serono, Novartis and Teva Pharmaceutical Industries Ltd.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Hemphill serves as an editorial board member of Neurocritical Care; holds stock options for serving on the scientific advisory board for Ornim Medical; receives research support from Cerebrotech Medical; funding as PI for hub site for Neurological Emergencies Treatment Trials Network; received a one-time speaking honorarium from Besins Critical Care, LLC and honoraria from Edge Therapeutics, Inc. for consulting; gave expert witness review and testimony on various cases related to stroke and neurocritical care.

1) Cerebrospinal fluid AB42 predicting early onset Parkinson disease and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Barrett interviews Dr. Henrik Zetterberg about his paper on cerebrospinal fluid A?42 predicting early onset Parkinson disease. Dr. James Addington is reading our e-Pearl of the week about Kennedy disease. In the next part of the podcast Dr. Mike Brogan interviews Dr. Laurie Gutmann about critical illness in polyneuropathy and myopathy. The participants had nothing to disclose except Drs. Zetterberg, Addington and Gutmann.Dr. Zetterberg serves as Senior Editor of the Journal of Alzheimer's disease; serves as Associate Editor of Alzheimer and Dementia; receives research support from the Swedish Research Council and Swedish State Support for Clinical Research. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Gutmann receives royalties from Up-to-Date Online from the publication of Hypokalemic and Hyperkalemic Periodic Paralysis; receives research support from Alexion Pharmaceuticals, Inc. and the NIH.

1) Venous thromboembolism in amyotrophic lateral sclerosis and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Lorne Zinman about his paper on venous thromboembolism in amyotrophic lateral sclerosis. Dr. James Addington is reading our e-Pearl of the week about SCN4A mutations. In the next part of the podcast Dr. Mike Brogan interviews Dr. Thomas Bleck about the management of status epilepticus in critical care. The participants had nothing to disclose except Drs. Burns, Zinman, Addington and Bleck.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Zinman serves on the scientific advisory board for the Data and Safety Monitoring Board NIH sponsored Tamoxiphen/Creatine ALS Study (non-profit entity); receives research support from the Garfield Weston Foundation, Public Health Agency of Canada, Canadian Institute of Health Research, ALS Society of Canada and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Bleck serves on the data safety and monitoring boards of the NIH sponsored RAMPART and ProTECT trials.

Utility of an immunotherapy trial in the evaluation of patients with presumed autoimmune epilepsy and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Sean Pittock about his paper on the utility of an immunotherapy trial in the evaluation of patients with presumed autoimmune epilepsy. Dr. James Addington is reading our e-Pearl of the week about logopenic-variant primary progressive aphasia. In the next part of the podcast Dr. Mike Brogan interviews Dr. Pratik Pandharipande about delirium in acute brain dysfunction in critically ill patients. The participants had nothing to disclose except Drs. Pandharipande, Pittock and Addington.Dr. Pandharipande received research support from Hospira Inc. and the NIH.Dr. Pittock received research support from Alexion Pharmaceuticals, Inc.; Guthy Jackson Charitable Foundation and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section.

Treatment of Movement disorders. Lesson of the Week interviews from May 2013

1) AAN paper on efficacy and safety of the therapeutic use of medical marijuana (Cannabis) in selected neurologic disorders and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Joanna Suski interviews Dr. Barbara Koppel about the AAN paper on efficacy and safety of the therapeutic use of medical marijuana (Cannabis) in selected neurologic disorders. Dr. Adam Numis is reading our e-Pearl of the week about myoclonic astatic epilepsy. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Greg Bergey about epilepsy therapeutics: Beyond medications for the refractory patient. The participants had nothing to disclose except Drs. Koppel, Numis and Bergey.Dr. Koppel serves as an editorial board member of Clinical Neurology.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Bergey was an expert witness in medicolegal activity over the past two years and receives research support from the NIH.

1) Migraine trait symptoms in migraine with and without aura and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Sowell interviews Dr. Tim Jürgens about his paper on migraine trait symptoms in migraine with and without aura. Dr. Adam Numis is reading our e-Pearl of the week about idiopathic normal pressure hydrocephalus. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Elinor Ben-Menachem about epilepsy therapeutics: Vigabatrin. The participants had nothing to disclose except Drs. Jürgens, Numis and Ben-Menachem.Dr. Jurgens serves as an editorial board member of ISRN Pain, serves as Visiting Editor of the Journal of Headache and Pain; is a consultant for Autonomic Technologies, Inc.; received speaker honoraria from Allergan, Inc., Pfizer Inc, MSD (commercial), Autonomic Technologies, Inc., DAGFA (non-profit), Kinderhospiz Sternenbrucke (non-commercial), received funding for Travel from MSD (commercial), Autonomic Technologies, Inc., DAGFA (non-profit), Kinderhospiz Sternenbrucke (non-commercial), Deutsche Migrane- und Kopfschmerzgesellschaft (non-commercial),) Deutsche Schmerzgesellschaft (non-commercial); serves as a board member of Deutsche Migrane- und Kopfschmerzgesellschaft; receives research support from Allergan, Inc. and Deutsche Migrane- und Kopfschmerzgesellschaft.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ben-Menachem serves as Editor of Acta Neurologica Scanidnavica; receives funding for travel from Eisai Inc., UCB, ElectroCore Medical, LLC.

1) Skin nerve a-synuclein deposits being a biomarker for idiopathic Parkinson disease and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Ratliff interviews Dr. Vincenzo Donadio about his paper on skin nerve ?-synuclein deposits being a biomarker for idiopathic Parkinson disease. Dr. Adam Numis is reading our e-Pearl of the week about cognitive impairment in pediatric multiple sclerosis. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Nathan Fountain about epilepsy therapeutics: Lacosamide. The participants had nothing to disclose except Drs. Fountain and Numis.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Fountain serves as Vice-President of the National Association of Epilepsy Centers; performs EEG lab work and EEG interpretation in his clinical practice (10% effort); receives research support from UCB, SK Life Sciences, Sunovion, Medtronic, NeuroPace; and the NIH.

1) Fingolimod after natalizumab and the risk of short-term relapse and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Vilija Jokubaitis about her paper on fingolimod after natalizumab and the risk of short-term relapse. Dr. Adam Numis is reading our e-Pearl of the week about cardiac cephalgia. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Madeline Fields about epilepsy therapeutics: Clobazam. The participants had nothing to disclose except Drs. Keegan, Jokubaitis and Numis.Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Jokubaitis received funding for travel to speak at a conference from Novartis, receives research support from MSBase Foundation and National Health and Medical Research Council.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.

Interviews from the 2013 AAN Annual Meeting

1) Rolandic epilepsy has little effect on adult life 30 years later and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Drs. Carol and Peter Camfield about their paper on how rolandic epilepsy had little effect on adult life 30 years later. Dr. Adam Numis is reading our e-Pearl of the week about lower cranial nerve dysfunction. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Jacqueline French about epilepsy therapeutics: Perampanel. There is different intro music, "Goofy Vocal Groove" by Dave Girtsman in this podcast. The song may be found at http://freemusicarchive.org/music/Dave_Girtsman/Silly_Songs/11_-_dave_girtsman_-_goofy_vocal_groove_kzz01_vbr. The original work was not changed ii any way and is licensed under a Attribution-NonCommercial-ShareAlike 3.0 International License. The participants had nothing to disclose except Drs. Fountain, Peter Camfield, Numis and French.Dr. Fountain serves as Vice-President of the National Association of Epilepsy Centers; performs EEG lab work and EEG interpretation in his clinical practice (10% effort); receives research support from UCB, SK Life Sciences, Sunovion, Medtronic, NeuroPace; and the NIH.Dr. Peter Camfield serves as an editorial board member of Journal of Child Neurology and Pediatric Neurology Epileptic Disorders Journal.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. French serves as an Associate Editor for Epilepsia; serves as an editorial board member of Lancet Neurology, Neurology Today, Epilepsy Currents; serves on the scientific advisory board for Electrocore, Epilepsy Therapy Project, UCB, Eisai Inc., SK Corporation, Marinus, Upsher-Smith Laboratories, Inc., Sunovion Inc., Vertex Pharmaceuticals, Novartis, Epilepsy Study Consortium; received paid travel to present findings at scientific meetings, present at investigators meetings attend advisory boards or give lectures from Acorda, UCB, Eisai, Inc., Johnson and Johnson, Upsher-Smith Laboratories, Inc., Novartis, Pfizer Inc, Eli Lilly and Company, LCGH, Vertex Pharmaceuticals, Supernus, Marinus Pharmaceuticals, Inc., SK Corporation; receives research support from Eisai, Inc., UCB, SK Corporation, Valeant Pharmaceuticals International, Upsher-Smith Laboratories, Inc., Vertex Pharmaceuticals, Pfizer Inc, Marinus Pharmaceuticals, Brain Sentinal, Epilepsy Research Foundation, The Milken Foundation, The Epilepsy Study Consortium and the NIH.

1) Lower stroke risk with lower blood pressure in hemodynamic cerebral ischemia and 2) Topic of the month: Mitochondrial disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. William Powers about his paper on lower stroke risk with lower blood pressure in hemodynamic cerebral ischemia. Dr. Roy Strowd is reading our e-Pearl of the week about Déjà vu. In the next part of the podcast Dr. Maria Farrugia interviews Dr. Doug Turnbull about the management of mitochondrial disorders. The participants had nothing to disclose except Drs. Southerland, Powers and Strowd.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Powers serves as an editorial board member of Stroke and Journal of Cerebral Blood Flow and Metabolism; serves on the scientific advisory board for Ontario Brain Institute Morehouse School of Medicine; receives research support from the NIH and UNC.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Intravenous valproate vs. metoclopramide vs. ketorolac for acute migraine and 2) Topic of the month: Mitochondrial disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Bickel interviews Dr. Benjamin Friedman about his paper on intravenous valproate vs. metoclopramide vs. ketorolac for acute migraine. Dr. Roy Strowd is reading our e-Pearl of the week about evaluating the exome. In the next part of the podcast Dr. Maria Farrugia interviews Dr. Robert Taylor about the investigations for mitochondrial disorders. The participants had nothing to disclose except Drs. Friedman and Strowd.Dr. Friedman serves on the scientific advisory board for MAP Pharmaceuticals.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Submandibular gland needle biopsy for diagnosis of Parkinson disease and 2) Topic of the month: Mitochondrial disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Brown interviews Dr. Charles Adler about his paper on submandibular gland needle biopsy for diagnosis of Parkinson disease. Dr. Roy Strowd is reading our e-Pearl of the week about nodes needing neurofascin. In the next part of the podcast Dr. Maria Farrugia interviews Dr. Andrew Schaefer about syndromes of mitochondrial disorders. The participants had nothing to disclose except Drs. Adler and Strowd.Dr. Adler serves on the scientific advisory board of Bachmann Strauss Dystonia and Parkinson Foundation; is a consultant for Allergan, Inc., Novartis, Merz Pharmaceuticals, LLC, XenoPort, Inc.; receives royalties from the publication of the book Parkinson's Disease and Movement Disorders; receives research support from Avid Radiopharmaceuticals, Department of Defense, Michael J. Fox Foundation for Parkinson's Disease Research, National Parkinson's Foundation and NIH.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Clinical characteristics and outcome of brain abscess and 2) Topic of the month: Mitochondrial disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Cupka interviews Dr. Matthijs Brouwer about his paper on clinical characteristics and outcome of brain abscess. Dr. Roy Strowd is reading our e-Pearl of the week about angioedema after tPA. In the next part of the podcast Dr. Maria Farrugia interviews Dr. Grainne Gorman about the fundamental principles of mitochondrial disorders. The participants had nothing to disclose except Drs. Brouwer, Strowd and Gorman.Dr. Brouwer receives research support from the Dutch Scientific Organization; received research support from the European Federation of Neurological Sciences and European Society of Clinical Microbiology and Infectious Diseases.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Gorman receives research support from the UK NIHR Biomedical Research Centre for Aging and Age-related disease, Research Fellow, awarded to the Newcastle upon Tyne Trust Foundation Hospitals NHS Trust.

Interviews from the 2013 AAN Annual Meeting

1) Guideline on prevention of stroke in nonvalvular atrial fibrillation. and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Gary Gronseth about AAN paper on prevention of stroke in nonvalvular atrial fibrillation. Dr. James Addington is reading our e-Pearl of the week about superficial siderosis. In the next part of the podcast Dr. Andy Southerland interviews Dr. Seemant Chaturvedi about Edoxaban, non-pharmaceutical options for stroke prevention in afib: ablation, atrial appendage occluder devices and any other options. The participants had nothing to disclose except Drs. Kissela, Gronseth, Addington, Southerland and Chaturvedi.Dr. Kissela serves on scientific advisory board for Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from the NIH, will receive compensation from Reata Pharmaceuticals, Inc. for serving on the Event Adjudication Committee for the BEACON study, which they are sponsoring and provides medico-legal reviews.Dr. Gronseth serves as Associate Editor for for Neurology®; serves on the editorial board of Neurology Now and receives research support from the American Academy of Neurology.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

1) Clinical specificities of patients with NMDA receptor antibodies encephalitis and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Menze interviews Dr. Jerome Honnorat about his paper on the clinical specificities of patients with NMDA receptor antibodies encephalitis. Dr. James Addington is reading our e-Pearl of the week about posterior interosseous nerve syndrome. In the next part of the podcast Dr. Mark McAllister interviews Dr. Seemant Chaturvedi about a brief review of new oral anticoagulant (Apixaban), reference clinical trial, indication and dosing. The participants had nothing to disclose except Drs. Addington and Chaturvedi.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

1) Guillain-Barre syndrome being associated with hepatitis E virus infection and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Bart Jacobs about his paper on Guillain-Barre syndrome being associated with hepatitis E virus infection. Dr. James Addington is reading our e-Pearl of the week about myelin-oligodendrocyte glycoprotein antibody. In the next part of the podcast Dr. Mark McAllister interviews Dr. Seemant Chaturvedi about a brief review of new oral anticoagulant (Rivaroxaban), reference clinical trial, indication and dosing. The participants had nothing to disclose except Drs. Burns, Jacobs, Addington and Chaturvedi.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Jacobs serves as an editorial board member for Journal of the Peripheral Nerve System; received funding for travel from Baxter International Inc. for a scientific meeting; received research support from the Netherlands Organization for Health Research and Development, Erasmus MC, Prinses Beatrix Spierfonds, GBS-CIDP Foundation International.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

1) ASA/clopidogrel combination confers better long term vascular protection in ASA failure and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Justin Sattin interviews Dr. Robert Cote about his paper on whether the combination of ASA/clopidogrel confers better long term vascular protection in ASA failure. Dr. James Addington is reading our e-Pearl of the week about hypoglycorrhachia. In the next part of the podcast Dr. Andy Southerland interviews Dr. Seemant Chaturvedi about a brief review of new oral anticoagulant (Dabigatran), reference clinical trial, indication and dosing. The participants had nothing to disclose except Drs. Cote, Addington, Southerland and Chaturvedi.Dr. Cote served on the scientific advisory board for Bayer Schering Pharma, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer Inc; serves on the scientific advisory board for DSMB for National Institute of Health (Point Study), Steering committee for the National Institute of Health (SPS3 study); is a consultant for Otsuka Pharmaceutical Co., Ltd.; received speaker honoraria from Boehringer Ingelheim, Merck Serono, Sanofi-aventis.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

Interviews with Bill Seely on frontotemporal dementia. Clinical presentations & bedside evaluation, diagnostic testing & genetics, therapeutics & future directions.

1) High dose midazolam infusion for refractory status epilepticus and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Dr. Jan Claassen about his paper on high dose midazolam infusion for refractory status epilepticus. Dr. Adam Numis is reading our e-Pearl of the week about genetic testing in early onset epileptic encephalopathies. In the next part of the podcast Dr. Matt Barrett interviews Dr. Vicki Shanker about clinical approach to non-Parkinson disease tremor. The participants had nothing to disclose except Drs. Claassen and Numis. Dr. Claassen serves as an editorial board member of Neurocritical Care.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Influence of age at surgical menopause influences cognitive decline and Alzheimer's pathology in older women and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Drs. Riley Bove and Philip De Jager about their paper on the influence of age at surgical menopause influences cognitive decline and Alzheimer's pathology in older women. Dr. Adam Numis is reading our e-Pearl of the week about parechovirus and neurologic disease. In the next part of the podcast Dr. Binit Shah interviews Dr. Anthony Lang about non-neurodegenerative causes of parkinsonism - drug-induced; structural: NPH, stroke, tumor; psychogenic. The participants had nothing to disclose except Drs. Burns, Bove, De Jager, Numis and Lang.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Bove receives research support from Partners Healthcare, National Multiple Sclerosis Society and the NIH.Dr. De Jager serves as an editorial board member of the Journal of Neuroimmunology; serves on the scientific advisory board for Teva Neuroscience, Genzyme/Sanofi; receives speakers' honoraria from Biogen Idec and Source Healthcare Analytics, LLC; receives research support from Biogen Idec, GlaxoSmithKline, Genzyme/Sanofi, Vertex Pharmaceuticals and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Lang served as an advisor for Abbott, Abbvie, Allon Therapeutics, Avanir Pharmaceuticals, Biogen Idec, Boerhinger-Ingelheim, Ceregene, Medtronic, Inc, Merck Serono, Novartis, NeuroPhage Pharmaceuticals, Teva Pharmaceutical Industries Ltd, UCB.; received research support from Brain Canada, Canadian Institutes of Health Research, Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, National Parkinson Foundation, Parkinson Society Canada, Tourette Syndrome Association, W. Garfield Weston Foundation; received publishing royalties from Saunders, Wiley-Blackwell, Johns Hopkins Press, Cambridge University Press; served as an expert witness in cases related to the welding industry.

1) Guideline on assessment and management of psychiatric disorders in individuals with multiple sclerosis and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Sarah Minden about AAN paper on assessment and management of psychiatric disorders in individuals with multiple sclerosis. Dr. Adam Numis is reading our e-Pearl of the week about airplane headache. In the next part of the podcast Dr. Binit Shah interviews Dr. Melissa Armstrong about diagnosis, management and prognosis of atypical parkinsonian disorders. The participants had nothing to disclose except Drs. Keegan, Minden, Numis and Armstrong.Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Minden received honoraria and travel reimbursement for meetings from Pfizer Inc, Merck Serono, Genentech, Inc., Novartis, and Avanir Pharmaceuticals; received research support from the National Multiple Sclerosis Society, the Center for Mental Health Services, and the Substance Abuse and Mental Health Services Administration; holds stock options in Merck Serono, Schering-Plough Corp, and GlaxoSmithKline.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Armstrong serves on the Level of Evidence Review Team for Neurology®; is an evidence-based guideline methodology consultant for the AAN; receives research support from Abbvie as local sub-investigator; received a 2011 Movement Disorders Society travel Scholarship to the MDS International Congress; and in 2010-2011 was partially funded by a Edmond J. Safra Fellowship at Toronto Western Hospital.

The New MS Drugs

1) Effect of head impacts on diffusivity measures in collegiate contact sport athletes and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Noah Kolb interviews Dr. Thomas McAllister about his paper on effect of head impacts on diffusivity measures in collegiate contact sport athletes. Dr. Adam Numis is reading our e-Pearl of the week about recurrent rhabdomyolysis. In the next part of the podcast Dr. Matt Barrett interviews Dr. Dan Weintraub about management of neuropsychiatric manifestations of Parkinson disease. The participants had nothing to disclose except Drs. McAllister, Numis and Weintraub.Dr. McAllister receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Weintraub serves as an editorial board member of Movement Disorders Journal; serves on the scientific advisory board of Pfizer Inc, Teva Pharmaceutical Industries Ltd., Avanir Pharmaceuticals, Merck Serono, Eli Lilly and Company, Biogen Idec, Lundbeck Inc., UCB, Bristol-Myers Squibb, CHDI Foundation, Inc, ADCS; receives fees from the University of Pennsylvania for licensing of Questionnaire for Impulsive-Compulsive Disorders in Parkinson disease; receives commercial funding for travel from Teva Pharmaceutical Industries Ltd.; gave expert testimony for defense in 2012-2013 in lawsuit related to impulse control disorders in Parkinson disease; receives research support from Novartis, Michael J. Fox Foundation for Parkinson's Research and the NIH.

1) Building foundations for improving health opportunities in sub-Saharan Africa and 2) Topic of the month: Maintenance of Certification. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matt Wong interviews Dr. Michael Finkel about his paper on building foundations for improving health opportunities in sub-Saharan Africa. Dr. Roy Strowd is reading our e-Pearl of the week about neurapraxia. In the next part of the podcast Dr. Michelle Mauermann interviews Dr. Kerry Levin on part two of the orientation of new processes to the Maintenance of Certification. The participants had nothing to disclose except Drs. Finkel, Strowd and Levin.Dr. Finkel gave expert testimony as a treating physician in 2012.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Levin serves as an editorial board member of Muscle and Nerve; serves on the scientific advisory board of the American Board of Psychiatry and Neurology; received reimbursement for travel to policy meetings and examination writing committees from the American Board of Psychiatry and Neurology; receives royalties from UpToDate.

1) Practice variability in brain death determination and 2) Topic of the month: Maintenance of Certification. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Jeff Frank about his paper on practice variability in brain death determination. Dr. Roy Strowd is reading our e-Pearl of the week about prion protein problems. In the next part of the podcast Dr. Elliot Dimberg interviews Dr. Janice Massey on part one of the orientation of new processes to the Maintenance of Certification. The participants had nothing to disclose except Drs. Burns, Strowd and Massey.Dr. Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Strowd serves on the editorial team for the Neurology Resident and Fellow Section. Dr. Massey serves on the AAN Board of Directors; the editorial board of Seminars in Neurology; and received unrestricted educational grants from Allergan, Inc. and Merz harmaceuticals, LLC for Annual Duke Advanced EMG and Chemodenervation Workshop.

More topics in biostatistics